ATLANTA--(BUSINESS WIRE)--MIV Therapeutics Inc. (OTCBB:MIVT - News; FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, has engaged leading strategic consulting firm QUILT Solutions giving the company access to significant experience, business development, sales and marketing expertise in lucrative European markets.

ADVERTISEMENT

QUILT Solutions is a leading strategic consulting firm for innovative business development solutions for the biopharmaceutical industry around the world. They provide tailor-made strategic services to clients in the U.S., Europe and Asia-Pacific areas, optimizing value creation in drug discovery, development, production, sales and marketing.

"We feel confident that partnering with QUILT will provide MIVT with the best possible business development resources as we bring product to the European marketplace," said Dr. Mark Landy, President of MIV Therapeutics. "We look forward to working with their team to build strong sales and marketing platform and an accelerated commercialization program to Europe."

The QUILT team has decades of experience building sales and marketing organizations in the world's leading pharmaceutical and biomedical companies.

MIVT recently announced that the Company has begun to generate revenues from recently acquired Biosync Scientific's eight CE-marked cardiovascular stents and related products targeting several multibillion-dollar markets, including Europe, Asia and India. This financial milestone further validated MIVT's mission to become a leading interventional cardiology company focused on delivering a broad suite of advanced cardiovascular stents and related products to patients, physicians and hospitals around the world.

The products also allow MIVT to accelerate the development of its brand and distributor relationships around the world as the Company prepares for the commercialization of its broad range of hydroxyapatite (HAp) coated stents, polymer-free drug-eluting stents, and other interventional cardiology products.

About QUILT Solutions (www.Quilt-Solutions.com)

QUILT Solutions is a leading strategic consulting boutique for innovative business development solutions for the biopharmaceutical industry around the world. We provide tailor-made strategic partnering services to clients in the USA, Europe and Asia-Pacific areas, optimizing value creation in drug discovery, development, production and marketing. Our inside knowledge of the industry and markets, together with language and cultural competence, makes us the partner of choice for biopharma and nutrition companies intending to develop their business in the global market place.

About MIV Therapeutics Inc.

MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting applications on cardiovascular stents and a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed to protect surrounding tissue from potentially harmful interactions with bare metallic stents. The Company's unique ultra-thin coating platform is derived from an organic material called hydroxyapatite (HAp) which has demonstrated excellent safety and biocompatibility in vivo animal studies. Hydroxyapatite is a porous material that makes up the bone mineral and matrix of teeth and is widely used today as a bone substitute material and for coatings on implantable fixation devices in orthopedic, dental and other applications. The Company's novel polymer-free drug eluting technologies based on Hydroxyapatite could also provide an attractive alternative to current polymer-based drug eluting coatings on the stent market, which have been associated with undesirable medical effects. The Company's drug eluting coatings are additionally designed to suit a broad range of implantable medical devices that could benefit from highly customizable drug release profiles. MIVT has a Collaborative Research Agreement (CRA) with the University of British Columbia and has received Government grant for its research program on the "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents," under the National Research Council-Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship, the Company is expected to complete its drug-eluting research and development program and to reach product commercialization stage.

For more information, please visit http://www.trilogy-capital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm. MIVT is traded on the Frankfurt, Germany, stock exchange under the symbol MIV.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "proposed," "expected," "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties including, without limitation, the potential for the unsuccessful closing by the Company of its Vascore acquisition, together with the raising of funding sufficient to continue with its operations and those contemplated by the Company as a consequence thereof, and the ability of the Company to raise sufficient funding and to continue to develop its various business interests as presently contemplated. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

MIV Therapeutics Inc.
Investor Relations, 604-301-9545, x14
Toll-free: 800-221-5108
Fax: 604-301-9546
investor@mivtherapeutics.com
http://www.mivtherapeutics.com/
or
Trilogy Capital Partners
Financial Communications
Ryon Harms, Toll-free: 800-592-6067
ryon@trilogy-capital.com